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Abstract	9 
Background	&	Aims	10 
Mucosal healing is associated with improved outcomes in patients with Crohn’s disease (CD), but 11 
assessment typically requires ileocolonoscopy. Calprotectin can be measured in fecal samples to 12 
determine luminal disease activity in place of endoscopy—this measurement is an important 13 
component of the treat to target strategy. We investigated whether levels of fecal calprotectin 14 
associate with subsequent CD progression. 15 
Methods	16 
We performed a retrospective study of 918 patients with CD (4218 patient-years of follow-up; 17 
median, 50.6 months; interquartile range [IQR], 32.8–76.0 months) managed at a tertiary medical 18 
center in Edinburgh, United Kingdom, from 2003 through 2015. Patients were included if they had 1 19 
or more fecal calprotectin measurement made 3 months or more following their diagnosis. We 20 
collected clinical data and fecal calprotectin measurements and analyzed these data to identify 21 
factors associated with a composite outcome of progression in Montreal behavior, hospitalization, 22 
and resection. 23 
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Results 1 
Increased level of fecal calprotectin at index visit was associated with subsequent progression of CD, 2 
independent of symptoms or disease location. The median level of fecal calprotectin at the index 3 
visit was 432 µg/g (IQR, 1365–998 µg/g) in patients who reached the composite endpoint vs 180 4 
µg/g (IQR, 50–665 µg/g) in patients who did not. In multivariable analysis, a cutoff of 115 µg/g 5 
calprotectin identified patients who met the endpoint with a hazard ratio on of 2.4 (95% CI, 1.8–3.1; 6 
P<.0001). 7 
Conclusion 8 
In a retrospective analysis of patients with CD, we found that measurements of fecal calprotectin 9 
made during routine monitoring can identify patients at risk for disease progression, independent of 10 
symptoms or disease location. It is therefore important to screen asymptomatic patients for mucosal 11 
inflammation and pursue complete resolution of inflammation.  12 
Keywords 13 
IBD; biomarker; prognostic factor; non-invasive  14 
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Introduction 1 
Crohn’s disease (CD), a form of inflammatory bowel disease (IBD), is characterized by relapsing 2 
episodes of intestinal inflammation and the accumulation of irreversible digestive damage. Prognosis 3 
is highly variable between individuals,
1
 such that the identification of patients at greatest risk of poor 4 
outcomes is an urgent research priority. Some clinical phenotypes, such as disease location and 5 
environmental factors such as smoking, have been clearly associated with poorer outcomes.
2,3
 6 
However, accurate prediction remains difficult. Over the past decade, there has been a paradigm 7 
shift away from treating until symptom resolution and towards mucosal healing as persistent 8 
subclinical bowel inflammation leads to poorer outcomes.
4–8
 However this has typically required 9 
ileocolonoscopy, which is invasive, expensive  and carries risk for patients.
9
  10 
Fecal calprotectin (FC) has become well-established as a biomarker of intestinal inflammation. 11 
Calprotectin is a 36.5 kDa protein that constitutes 60% of the contents of granules in neutrophils.
10
 12 
Its use as a screening test to distinguish IBD from irritable bowel syndrome is well-supported by 13 
multiple studies, with an AUROC of 0.95 in meta-analysis.
11
 Several groups have demonstrated that 14 
FC correlates well with endoscopic measures of disease activity.
12–16
 There has been greater 15 
uncertainty of its role in small bowel CD, but more recently FC has been shown to correlate well with 16 
both MRI
17
 and capsule endoscopy findings.
18,19
 17 
The use of FC as a prognostic marker has been demonstrated in the context of medically- and 18 
surgically-induced remission.
20–22
 In both contexts, baseline FC predicts disease flare over a follow-up 19 
period of two years, though there is also a rise notable in FC 3-4 months prior to clinical disease 20 
flare. The recent CALM study has demonstrated the effectiveness of a treat to target strategy 21 
incorporating FC in Crohn’s disease.
23
 However, it has still not yet been demonstrated whether 22 
elevations in FC, irrespective of clinical symptoms, are associated with disease progression. This 23 
information would provide further support to the principle of treating beyond symptoms.  24 
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We aimed to use a large, extensively-phenotyped cohort of CD patients followed over time to 1 
determine the value of FC to predict progression of disease. We focused on endpoints associated 2 
with digestive damage: progression of Montreal behaviour
24
, surgical resection or hospitalization for 3 
severe flare. 4 
Methods 5 
This was a retrospective cohort study of CD patients managed at the Western General Hospital, 6 
Edinburgh, UK, a teaching hospital that cares for secondary- and tertiary-referred patients with IBD. 7 
The primary inclusion criteria were a diagnosis of CD and at least one FC more than three months 8 
post-diagnosis. The a priori primary endpoint was a composite of progression in Montreal luminal 9 
disease behavior (B1 to B2/B3 or B2 to B3), hospitalization for flare and resectional surgery. These 10 
individual components were also defined as separate secondary endpoints. In order to reduce the 11 
possibility of merely measuring the FC at the time of the disease flare that caused the endpoint, any 12 
events that happened within 90 days after the index FC were regarded as having already happened 13 
and were not included in the endpoint analysis. 14 
We obtained FC data from the Edinburgh FC Registry (EFCR), a record of every FC done in Edinburgh 15 
since its introduction in 2003. Patients in this initial cohort had their first FC between 2003 and 2014 16 
and were followed up until 2015. Fecal calprotectins were requested as part of routine monitoring 17 
and also directed by patients’ symptoms. These data represent a convenience sample, and include 18 
all patients tested during that period who met our inclusion criteria. 19 
We matched these data to existing research and clinical databases to identify patients with a known 20 
diagnosis of CD. We then interrogated the electronic and paper medical records to obtain 21 
information on demographics, symptoms, disease location and behavior over time, hospitalizations, 22 
surgical procedures, investigations and drug therapy. Disease location and behavior were classified 23 
according to the Montreal classification.
24
 Changes in disease behavior were defined as occurring 24 
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when the first investigation that demonstrated the change was performed, for example an MRI scan 1 
showing stricturing small bowel disease. 2 
Patients were regarded as symptomatic either by Harvey Bradshaw Index (HBI) > 4 and/or by 3 
physician global assessment of active symptomatic luminal disease
25
. Each of the previous medical 4 
therapies was categorized as having ever taken versus never, with immunomodulators defined as 5 
azathioprine, mercaptopurine and methotrexate. Data were stored in a Microsoft Access 2003 6 
database (Microsoft, Redmond, WA, USA).) 7 
FC collection kits were given to patients and samples returned to the hospital biochemistry 8 
laboratories either directly or via their GP practice (samples forwarded the same day). Upon arrival 9 
at the laboratories samples are stored at -20 °C. FC was measured using a standard enzyme-linked 10 
immunosorbent assay (ELISA) technique (Calpro AS, Norway). All assays were performed utilizing the 11 
same protocol in the Department of Clinical Biochemistry at the Western General Hospital, 12 
Edinburgh. The manufacturer’s reference range for distinguishing inflammatory bowel disease from 13 
functional gut disorders is >50 µg/g. 14 
Statistical analysis was done using R 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria). 15 
The Mann Whitney U test was performed for continuous non-parametric data, while Fisher’s exact 16 
tests were done for categorical data. Survival analysis was performed using Kaplan Meier and Cox 17 
proportional hazards models.
26
 For the survival models, we have reported the outcome as the 18 
proportion with maintained digestive health, i.e. the inverse of our primary endpoint. Patients were 19 
excluded from the specific analysis of progression in Montreal behavior if they were already B3 at 20 
baseline. 21 
FC was analyzed using log-transformed data and using a predefined threshold of 250 µg/g. The 22 
optimum threshold for FC on survival analysis was then explored by examining the p values of the 23 
likelihood ratio test and the Akaike Information Criteria for Cox proportional hazard models. Variable 24 
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selection for multivariable models was done using a stepwise backwards method based on Akaike 1 
Information Criterion. We performed Cox proportional hazards analyses of the effect of drug therapy 2 
up to 3 months pre or 6 months post fecal calprotectin on the primary outcome; for this analysis, 3 
patients who had disease progression within the first six months or who were censored in that 4 
period were excluded from analysis. The multistate transition data for disease progression in the 5 
overall cohort was done using the empirical transition matrix method.
27
  6 
The principal analysis was done using the first FC for each patient where there was more than one. 7 
Owing to the retrospective nature of this dataset, these were not taken at uniform intervals. 8 
Exploratory analysis of multiple FCs was performed using the median for each rolling six-month 9 
period centered on each month following diagnosis and stratified by progression in Montreal 10 
behavior. FCs were excluded from this analysis where the patient was symptomatic at the time of 11 
sampling. 12 
This study was conducted as a service evaluation using data collected routinely as part of clinical 13 
care, and therefore following guidance from the UK Health Research Authority did not require 14 
specific ethical approval or consent. 15 
Results  16 
We identified 918 CD patients meeting our inclusion criteria (Figure 1). 61.1% were female, and 17 
median age at the index FC measurement was 40.7 years (interquartile range [IQR] 28.5-54.8) (Table 18 
1). Median follow-up time was 50.6 months (IQR 32.8-76.0), with a total of 4218 patient-years of 19 
follow-up across the cohort. At diagnosis, 81% had an inflammatory (B1) phenotype, 12% stricturing 20 
(B2) and 8% penetrating (B3). By 30 years post-diagnosis, the proportions of B1, B2 and B3 were 21 
estimated as 29%, 36% and 36% respectively (Figure 2). FC was significantly higher in patients with 22 
L3 (median 315[IQR 90 – 866] µg/g) and L2 disease (median 289 [IQR 69 – 909] µg/g) than in those 23 
with L1 disease (median 180 [IQR 65 – 445 µg/g]; p<0.0001). 24 
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Demographic and biomarker data on the cohort stratified by whether the patients reached the 1 
composite endpoint or not are shown in table 2. On univariable cox proportional hazards analysis, FC 2 
was strongly associated with an elevated risk of reaching the primary endpoint (Table 3), with a 3 
hazard ratio (HR) of 1.79 (95% CI 1.50 – 2.14, p = 1.9×10
-10
) for log10(FC). The only other blood tests 4 
nominally associated with FC on univariable analysis were CRP (p=0.016), hemoglobin (p=0.011) and 5 
platelets (p=0.003). There were also associations with younger age at diagnosis (p=0.010), female 6 
sex (p=0.021), prior immunomodulator use (p=0.012), symptoms at index visit (p=1.2×10
-7
). Smoking 7 
status, previous intestinal resection, previous anti-TNF and time period of FC measurement 8 
(pre/post 2008) use were not associated with the primary endpoint, nor was there a significant 9 
difference in the time since diagnosis at the index FC. 10 
On multivariable Cox proportional hazards analysis, disease progression was independently 11 
associated with elevated FC, female sex, younger age, ileal/ileocolonic disease, previous 12 
immunomodulator use and symptoms (Table 3). 13 
A further analysis was performed to explore the effect of changes in treatment before and after 14 
measurement of calprotectin (Supplementary Table 1). This was restricted to patients who did not 15 
have disease progression and were not censored within the first six months. There were no 16 
significant associations with changes in medication in the three months leading up to the 17 
measurement of fecal calprotectin. Use of steroids in the six months following calprotectin was 18 
significantly associated with disease progression (HR 1.5 [95% CI 1.16 - 2.03], p=0.003). However, 19 
this was no longer significant in a multivariable analysis that also included the FC result 20 
(Supplementary Table 2). 21 
Above a threshold FC of 250 µg/g, the hazard ratio for reaching the primary endpoint was 1.9 (95% 22 
CI 1.5 – 2.3, p = 5.5×10
-8
, figure 3A). Using analysis of different thresholds of FC (Supplementary 23 
Figure 1), the most significant difference in progression to the primary composite endpoint with a 24 
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cut-point of 115 µg/g (figure 3B) yielding a hazard ratio on multivariable analysis of 2.4 (95% CI 1.8 – 1 
3.1, p = 7.2×10
-10
).  Differences in progression were seen in all three principal Montreal locations (L1, 2 
L2 and L3; Supplementary Figure 2), in all three secondary endpoints (Supplementary Figure 3) and 3 
independent of symptom status at the index visit (Supplementary Figure 4).  4 
Using the Kaplan-Meier estimates, the positive predictive value of an index FC >115 µg/g was 28%, 5 
43%, 52% and 59% at 2, 4, 6 and 8 years respectively. The negative predictive value of an index FC 6 
≤115 µg/g was 88%, 80%, 74% and 65% at 2, 4, 6, and 8 years respectively. 7 
In a sensitivity analysis by quartiles of time from diagnosis to first fecal calprotectin, the association 8 
between calprotectin and disease progression was seen for quartiles 2 to 4, but not for the patients 9 
in the first quartile; these patients had 3 to 15.5 months between diagnosis and first fecal 10 
calprotectin (Supplementary Figure 5). 11 
We performed an exploratory analysis using all of the available CD FC data and excluding FC taken 12 
when patients had symptoms. This analysis included 1456 FCs from 396 patients. The rolling median 13 
FC can clearly be seen to differ between those 35/396 patients with a subsequent progression in 14 
Montreal behavior and those that did not (Supplementary Figure 6). 15 
Discussion 16 
This study demonstrates that elevated FC is associated with increased disease progression, both as 17 
defined by a composite primary endpoint of advance in Montreal luminal behavior, surgical 18 
resection and hospitalization and by each of these endpoints when considered individually.  19 
Mucosal healing is recognized as a target for therapy in Crohn’s disease, with poorer prognosis and a 20 
higher risk of surgery associated with increased endoscopic disease activity
4–8
 There is a strong 21 
correlation between FC, endoscopic disease activity and ulcer depth.
12,28
 Our data show more 22 
directly that elevated FC can be used as a marker of increased risk of progression. 23 
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Although absolute index FC levels were lower in L1 patients, FC better predicted poorer outcomes in 1 
patients with L1/L3 rather than L2 disease distribution. Patients with active colonic disease may be 2 
more likely to exhibit symptoms, and thus have earlier intervention. In contrast, patients with active 3 
ileal disease may tolerate a higher level of subclinical inflammation, resulting in delay of treatment  4 
with a greater risk of progression and complications.   5 
Other variables associated with an adverse outcome in our analysis included younger age, which has 6 
previously been identified as an adverse prognostic factor
1
, and previous immunomodulator use 7 
which is likely to be a marker for a more aggressive prior disease course. Symptomatically active 8 
disease was associated with an increased rate of disease progression, independently of elevated FC.  9 
This validates a treat-to-target approach aiming for a combination of resolution of symptoms as well 10 
as mucosal healing, with FC a marker of the latter. 11 
Thresholds for prediction of disease relapse have varied across the literature, influenced by the 12 
disease cohort being studied and the assay used. Several studies have identified a cut-off of 250 µg/g 13 
as being useful to distinguish active from inactive disease.
20,22,29
 In the present study, the optimal 14 
separation between survival curves for progression of disease was seen using a lower threshold of 15 
115 µg/g, suggesting that lower levels of inflammatory activity may still be associated with an 16 
adverse outcome. However, any such threshold needs to be interpreted in the context of the 17 
methods of FC extraction and measurement. For example, others have shown significant variability 18 
in FC measurement between weight-based and other methods of FC extraction and similarly when 19 
comparing ELISA kits from different manufacturers’.
30,31
 20 
We have shown that elevated FC at any point in disease course beyond the first year correlates with 21 
poorer outcome. Previous studies have demonstrated an increase in symptomatic relapse in patients 22 
with elevation of FC;
20–22
 our study further indicates that this is associated with an increase in 23 
disease progression. The CALM study has recently demonstrated better outcomes at 52 weeks when 24 
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a strategy incorporating symptoms, CRP and FC was compared with clinical disease activity alone.
32
 1 
Together, these data now clearly support a treat-to-target strategy combining a patient-reported 2 
symptom score with FC as a marker of mucosal inflammation. 3 
Strengths of the present study include the large number of patients and duration of follow-up, with 4 
a median follow-up time following index FC of greater than four years. A clinically relevant definition 5 
of disease progression was selected a priori, and rich phenotype information was available. 6 
Restricting measurement of endpoints to at least 90 days after the index FC should reduce bias from 7 
measuring disease activity associated with an exacerbation that went on to cause hospital admission 8 
or surgical resection. It can also be observed that the survival curves in figures 3–6 continue to 9 
separate for many months after the index FC. This suggests that identification of mucosal 10 
inflammation at any point in patient follow up, even at relatively modest levels previously 11 
considered acceptable (i.e. FC 115-250ug/g), should warrant careful monitoring and low threshold 12 
for treatment escalation decisions.  13 
Limitations of this study relate to its retrospective nature. FCs were not collected at fixed intervals, 14 
but as determined by the treating clinician. However, routine monitoring of FC including in 15 
asymptomatic patients was established quite early on in Edinburgh after the full roll-out of the test 16 
in 2005. The study was also performed at a single centre, which may reduce heterogeneity but at the 17 
expense of generalizability. Nonetheless, although the Western General Hospital is a referral centre, 18 
it also has a large secondary care population from the local catchment. Finally, medication data were 19 
completed as accurately as was possible, but it is possible some courses of steroids, particularly 20 
those in primary care, may have been missed. This is unlikely to have introduced any systematic bias. 21 
In conclusion, we have shown in this study that elevated fecal calprotectin is associated with an 22 
increased risk of disease progression over time in Crohn’s disease. Further studies should continue 23 
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to explore the utility of repeated FC measurements, and to assess whether intervention based on FC 1 
can alter disease outcome. 2 
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Table 1 – Baseline demographics of the cohort (n=918) 
Variable  Median (IQR) / 
Number (%) 
Sex Female 561 (61.1%) 
Age at diagnosis/years 27.4 (20.1 - 42.8) 
Age at calprotectin/years 40.7 (28.5 - 54.8) 
Months to first calprotectin 75.5 (15.5 - 183.8) 
Year of first calprotectin 2010 (2008 - 2011) 
(Range 2003 – 2014) 
Smoking at diagnosis 
 
Current 229 (32.5%) 
Ex 101 (14.3%) 
Never 375 (53.2%) 
Montreal location 
 
L1±L4 289 (31.7%) 
L2±L4 328 (36.0%) 
L3±L4 288 (31.6%) 
Isolated L4 6 (0.7%) 
Montreal behavior at diagnosis B1 741 (80.7%) 
B2 106 (11.5%) 
B3 71 (7.7%) 
Montreal behavior at index calprotectin B1 564 (61.4%) 
B2 200 (21.8%) 
B3 154 (16.8%) 
New medication in 3 months prior to fecal calprotectin 
Steroids 91 (9.91%) 
Immunomodulator 58 (6.32%) 
Anti-TNF 16 (1.74%) 
Any of these 146 (15.90%) 
New medication in 6 months following fecal calprotectin 
Steroids 170 (18.52%) 
Immunomodulator 105 (11.44%) 
Anti-TNF 47 (5.12%) 
Any of these 239 (26.03%) 
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Table 2 Demographics and investigations at index visit stratified 
by whether individuals reached the composite primary endpoint 
of progression in Montreal behavior, surgical operation or 
hospitalization 
Variable Primary endpoint P 
Not reached Reached 
Sex M 235 (42.4%) 105 (32.5%) 0.005 
 F 320 (57.7%) 217 (67.4%)  
Age at diagnosis/years 28.2 (20.9 - 45.0) 24.7 (17.9 - 38.1) 2.3×10
-4
 
Age at calprotectin/years 41.9 (30.0 - 56.3) 38.0 (26.7 - 49.8) 2.7×10
-4
 
Months to first calprotectin 69.3 (13.4 - 183.8) 85.1 (20.0 - 189.5) 0.234 
Montreal location L1 167 (30.3%) 110 (34.5%) 1.7×10
-4
 
 L2 224 (40.6%) 88 (27.6%) 
L3 159 (28.8%) 117 (36.7%) 
Smoker at visit No 263 (75.1%) 142 (68.9%) 0.115 
Yes 87 (24.9%) 64 (31.1%)  
Previous resection 231 (41.6%) 146 (45.3%) 0.289 
Previous immunomodulator 255 (45.9%) 166 (51.6%) 0.123 
Previous anti-TNF 110 (19.8%) 68 (21.1%) 0.664 
Symptomatic at index visit 195 (53.4%) 162 (78.3%) 2.4×10
-9
 
Investigation n  
Fecal calprotectin (ug/g) 877 180 (50 - 665) 432 (136 - 998) 6.9×10
-12
 
CRP (mg/L) 375 7 (3 - 19) 10 (4 - 27) 0.023 
ESR (mm/hr) 202 21 (11 - 36) 26 (14 - 41) 0.045 
Albumin (g/L) 350 40 (36 - 43) 38 (32 - 43) 0.097 
Hemoglobin (g/L) 
(scaled to male range) 
500 148 (139 - 155) 145 (133 - 154) 0.009 
WCC (×10
9
/L) 507 7.5 (5.9 - 9.4) 7.3 (5.8 - 9.5) 0.785 
Platelets (×10
9
/L) 489 277 (225 - 342) 305 (249 - 377) 4.9×10
-4
 
 
Values shown are medians (interquartile ranges) and numbers (percentages) as appropriate. 
P values calculated using Mann Whitney U and Fisher’s exact tests for continuous and categorical 
data respectively.  
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Table 3 Univariable and multivariable analyses using Cox 
proportional hazards models for time to reaching primary 
endpoint 
Variable Univariable Multivariable 
HR (95% CI) p HR (95% CI) p 
Sex (female) 1.31 (1.04 - 1.65) 0.021 1.66 (1.23 - 2.24) 0.001 
Age at diagnosis/years 0.99 (0.98 - 1.00) 0.010   
Age at 
calprotectin/years 
0.99 (0.98 - 1.00) 0.001 0.99 (0.98 - 1.00) 0.010 
No ileal involvement 
(Montreal L2) 
0.66 (0.51 - 0.84) 7.9×10
-4
 0.60 (0.44 - 0.82) 0.001 
Previous 
immunomodulator 
1.32 (1.06 - 1.64) 0.012 1.39 (1.04 – 1.84) 0.024 
Previous anti-TNF 1.12 (0.86 - 1.46) 0.411   
Symptomatic at index 
visit 
2.45 (1.76 - 3.42) 1.2×10
-7
 2.07 (1.46 – 2.93) 4.1×10
-5
 
Fecal calprotectin 
(ug/g)* 
1.79 (1.50 - 2.14) 1.9×10
-10
 1.49 (1.17 – 1.89) 0.001 
CRP (mg/L)* 1.44 (1.07 - 1.93) 0.016   
Hemoglobin (g/L) 
(scaled to male range) 
0.99 (0.98 - 1.00) 0.011   
Platelets (x10^9/L 1.00 (1.00 - 1.00) 0.003   
* Variable log10 transformed prior to use in the model. Hazard ratio is for each 10-fold increase in the 
variable. 
HR: Hazard Ratio; CI: Confidence Interval 
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Figure legends 
Figure 1 – Derivation of the cohort of patients with Crohn’s disease, fecal 
calprotectin (FC) and follow-up data 
Figure 2 – Disease progression over time in the whole cohort as estimated by the 
empirical transition matrix method 
Figure 3 – Kaplan-Meier plot of time to reaching primary endpoint stratified by 
fecal calprotectin > 250 µg/g (A) and > 115 µg/g (B) at index visit 
The outcome of maintained digestive health is defined here as the inverse of the primary study 
endpoint (a composite of progression in Montreal behavior, hospitalization or surgery) 
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 30,454 patients with ≥1 FC (2003-2015) 
1339 with Crohn’s disease 
771 with UC 
343 other diagnoses 
28,001 not yet classified 
977 fully phenotyped 
362 insufficient records 
918 with ≥1 FC ≥3m post diagnosis 
877 with ≥12m f-up post FC 
59 without FC ≥3m  
post diagnosis 
41 with <12m follow-up 
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What	you	need	to	know	
Background and Context 
Fecal calprotectin is a marker of luminal Crohn’s disease (CD) activity. We investigated whether fecal 
calprotectin associates with subsequent CD progression. 
Findings 
We have now shown that an increased fecal calprotectin is associated with a long-term increase in 
disease progression, including hospitalisation, surgery and advance in Montreal behaviour. 
Implications for patient care 
It is important to screen asymptomatic patients for mucosal inflammation and pursue complete 
resolution of inflammation. 
